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Abstract 
Background: ST2 is a circulating biomarker that is well established for predicting outcome 
in heart failure (HF). This is the first study to look at ST2 concentrations in optimally treated 
patients with stable but significant left ventricular systolic dysfunction (LVSD) compared to 
patients with severe aortic stenosis (AS). 
Methods: Two cohorts were retrospectively studied: 94 patients undergoing transcatheter 
aortic valve implantation for severe AS (63 with normal ejection fraction [EF] and 31 with 
reduced EF), and 50 patients with severe LVSD from non-valvular causes. ST2 pre-
procedural samples were taken, and repeated again at 3 and 6 months. Patients were 
followed-up for 2 years. Data was analyzed using SPSS software. 
Results: Baseline concentrations of soluble ST2 did not differ significantly between the HF 
group and AS group with normal EF (EF ≥ 50%). However, in the AS group with a low EF 
(EF < 50%) ST2 concentrations were significantly higher that the HF group (p = 0.009). New 
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York Heart Association class IV HF, baseline N-terminal pro-B-type natriuretic peptide and 
gender were all independent predictors of soluble ST2 (sST2) baseline concentrations. 
Conclusions: Raised ST2 concentrations in the context of severe AS may be a marker for 
subclinical or clinical left ventricular dysfunction. More research is required to assess its use 
for assessment of prognosis and response to treatment. 
Key words: ST2, biomarkers, aortic stenosis, transcatheter aortic valve implantation, 
heart failure 
 
 
Introduction 
ST2 is a circulating biomarker of the interleukin (IL) 1 gene family that binds with the 
IL-33 ligand. This exists either in a transmembrane receptor (ST2L) which binds to 
circulating IL-33 and reduces tissue fibrosis, or a soluble receptor (sST2) which blocks this 
beneficial effect by binding itself to IL33. Elevated plasma concentrations of ST2 are 
powerful predictors of death, pump failure and arrhythmias [1]. It is now a well validated 
biomarker for predicting outcome in heart failure (HF) [2–4]. It may also be useful in the 
serial monitoring of patients with HF [5]. 
 ST2 is thought to be produced in the peripheral vasculature [6] in response to 
increased biomechanical stress on the myocardium [7]. ST2 may also be involved with 
remodeling in left ventricular hypertrophy (LVH), and it is thought to be a marker of cardiac 
fibrosis. However, its precise pathophysiological roles in HF and LVH remain unclear. Since 
severe aortic stenosis (AS) and established HF are associated with biomechanical stress on 
the myocardium and patients with severe AS additionally have microvascular ischemia, under 
examination was whether the ST2 concentrations in patients with severe AS were similar to 
those in patients with established HF who were on optimal medical therapy.  
 
Methods 
Ethical approval of the protocol and for collection of samples to measure and analyze 
biomarker concentrations were obtained from the London (Dulwich) and East Midlands 
National Research Ethics Service Committee. 
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A total of 144 patients were retrospectively studied, comprising 50 patients with 
severe left ventricular (LV) systolic dysfunction (LVSD) due to non-valvular causes and 94 
patients undergoing transcatheter aortic valve implantation (TAVI) for severe AS. Between 
October 2011 and October 2012, 50 patients were recruited with chronic HF in the New York 
Heart Association (NYHA) classes I–III and LV ejection fraction (EF) ≤ 40% from the HF 
clinics at Kings College Hospital, London. All patients were on optimum tolerated HF 
medications, comprising of angiotensin-converting enzyme inhibitors or angiotensin receptor 
blockers, beta-blockers, mineralocorticoid receptor antagonists and diuretics. The target doses 
were determined according to current guidelines [8]. Exclusion criteria included a 
cardiovascular admission or change in HF medication within four weeks of recruitment, a 
planned cardiovascular admission, significant renal impairment (estimated glomerular 
filtration rate [eGFR] < 20 mL/min/1.73 m2), or the inability or unwillingness to consent. 
This HF cohort has been described previously [5]. 
Additionally, 97 patients were studied who had undergone TAVI from March 2009 to 
May 2012 for severe AS. 3 patients were excluded for not having blood samples taken for 
biomarker analysis; therefore, 94 patients comprised the AS group. Patients who had TAVI 
for “valve in valve” replacement for aortic regurgitation were also excluded. The details of 
investigations and outcomes were obtained from electronic databases and patient records. 
ST2 samples were drawn prior to the interventional procedure. 
The blood samples were obtained by venepuncture after the patients had rested for 20 
in a semi-recumbent position and collected in tubes containing ethylenediaminetraacetic acid. 
The serum ST2 was measured by enzyme linked immunosorbent assay (R&D Systems 
Europe, Ltd, Abingdon, UK). The ST2 assay contains an NS0-expressed recombinant human 
ST2 and has been shown to accurately quantify the recombinant factor. The intra-assay 
precision was 5.6%, 4.4% and 4.5% and the inter-assay precision was 7.1%, 5.4% and 6.3% 
at 5.4, 12.6 and 20.6 μg/L, respectively. The limit of detection was 0.005 μg/L and the 
reference range is 6.74–20.4 μg/L [9]. 
The LV dimensions, function and mass were derived from the transthoracic 
echocardiographic evaluations. The TAVI procedures were performed by experienced 
cardiologists using Sapien 3 and Sapien XT valves (Edwards Life Sciences, Irvine, CA, 
USA). Serial ST2 concentrations were measured between 3 and 6 months from baseline. At 
the end of a 2 year follow-up, the primary end-point was all-cause mortality. 
 
Statistical analysis 
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Statistical analyses were performed using the IBM® SPSS® package version 22 (IBM 
Corporation, Armonk, NY, USA). Normally distributed data were expressed as mean and 
standard deviation and the groups were compared using the Student t-test. Non-normally 
distributed data were expressed as medians plus interquartile range and were compared using 
the Kruskall-Wallis and Mann-Whitney-U tests. Categorical data were summarized using 
numbers and percentages and the groups were compared with respect to these data using the 
χ2 test. Stepwise multiple linear regression was used to identify the predictors of baseline 
sST2 concentration using a probability (F) of 0.05 for entry into and 0.10 for removal from 
the model. Survival analysis was performed on all-cause mortality and survival curves were 
plotted using the Kaplan-Meier method and compared using the log-rank test. A value of p < 
0.05 considered statistically significant.  
 
Results 
The baseline characteristics of patients are shown in Table 1. A total of 144 patients 
with an average age of 78 years were included in the analysis, of whom 89 were male and 55 
were female. Of these patients, 113 (78.4%) had an LVEF ≥ 50%, and 31 (21.6%) had an 
LVEF < 50%. When 40% was used as the cut-off value for EF, 132 (91.7%) patients had an 
EF ≥ 40% and 12 (8.3%) had an EF < 40%. Using 40% as the cut off for EF had little impact 
on the final statistical analysis (data not shown). Twenty-four out of 144 (16.7%) patients had 
renal dysfunction, which was defined as an eGFR < 45 mL/min/1.73 m2. Of the 50 patients 
who comprised the HF group, 24 had ischemic cardiomyopathy and 26 had non-ischemic 
cardiomyopathy.  
Baseline concentrations of sST2 did not differ significantly between the HF group and 
those in the AS group who had EFs ≥ 50%. The baseline concentrations of sST2 were 
significantly higher for patients in the AS group who had low EFs (< 50%) compared with 
those in the HF group (p = 0.009) (Fig. 1), a finding that did not change appreciably when the 
analysis was repeated using an EF cut-off value of 40% (Fig. 2). The latter analysis was 
performed in an attempt to standardize the definition of LV systolic function, because the HF 
cohort had an EF cut-off value of 40%. 
A multivariate linear regression analysis was performed to determine the factors that 
predict the baseline sST2 concentration using a stepwise method and the following variables: 
baseline N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentration, cohort (AS 
with EF < 50% and AS with EF > 50%), age, eGFR, gender, hypertension, diabetes, 
hypercholesterolemia, baseline QRS, LV mass, baseline EF, baseline end-diastolic volume, 
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left atrial volume, and NYHA class (I–IV). NYHA class IV HF, baseline NT-proBNP level, 
and gender were identified as independent predictors of baseline sST2 concentrations (Table 
2). 
Figure 3 presents the Kaplan-Meier survival curves. The log-rank test did not 
determine a significant difference between the cohorts that had baseline ST2 concentrations 
that were either above or below the median concentration (p = 0.463) (Fig. 3). 
Significant differences were evident between the HF group and the AS subgroup with 
an EF > 50% and between the HF group and the AS subgroup with EF < 50% with respect to 
all-cause mortality (log-rank test: p < 0.001) (Fig. 4). These differences persisted when EF 
was changed to a cut-off value of 40% and when 30-day mortality was excluded from the 
analysis (data not shown). This is consistent with current knowledge from previous studies 
[10]. 
A comparison of survival according to the baseline NT-proBNP levels that were 
dichotomized at the median concentration, showed a significant difference with respect to 
prediction of death (log-rank; p = 0.002) (Fig. 5). 
The receiver operating curve analysis revealed an area under the curve (AUC) of 
0.580 for all-cause mortality at 2 years. The serial ST2 concentrations determined from 3 to 6 
months from baseline showed a change of +0.88 μg/L in the HF group and a change of +0.47 
μg/L in patients with AS who had undergone TAVI, a difference that was not significant. The 
AUC for all-cause mortality at 2 years improved to 0.602 when the analysis included the 3–6-
month ST2 concentrations. 
 
Discussion 
ST2 has been extensively studied and validated as a biomarker for HF [4, 11] but it is 
much less well described in association with severe AS. Bartunek et al. [6] demonstrated that 
ST2 concentrations in the coronary sinus in AS were non-significantly different to controls. 
Therefore, ST2 production is likely to be extra-cardiac, even though its actions directly affect 
the myocardium. The presence of biomechanical stress is believed to initiate production of 
ST2 in the vascular endothelium, which in turn binds to IL-33 receptors to inhibit or promote 
fibrogenesis [6, 7]. 
Findings from one small study found elevated ST2 concentrations in stenotic but non-
regurgitant aortic valve leaflet tissue [12]. This may reflect the difference in pathological 
changes that the aortic valve undergoes. Although, it is unlikely that the degree of ST2 
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expression within valve tissue would affect serum concentrations significantly, this has yet to 
be formally tested.  
The findings from the present study indicate that the ST2 concentrations were 
similarly elevated in patients with HF and in those with severe AS. However, the ST2 
concentrations were significantly higher in patients with severe AS and LV systolic 
dysfunction, which concurs with a poorer prognosis in this group of patients [13]. This result 
was unexpected, because LVH from severe AS is not usually associated with the same levels 
of myocardial fibrosis as those seen in patients with severe LVSD. 
The presence of raised ST2 concentrations may be an early warning sign for 
subclinical LVSD or decompensated AS in patients with AS. While it is yet to be determined 
whether measuring ST2 concentrations could help clinicians decide when to intervene, the 
findings from one study have demonstrated that raised ST2 concentrations may predict a 
poorer prognosis in asymptomatic patients with severe AS [14]. 
ST2 has emerged as marker of inflammation, fibrosis, cardiac stress and remodeling. 
In many studies ST2 has been shown to be a BNP independent predictor of cardiac and all-
cause mortality. ST2 reflects the dynamic changes in a failing heart and thus parallel the 
myocardial remodeling and risk of cardiac events. Its value is potentially more significant in 
patients with normal systolic LV function but with LVH.  
Sample size in the current study was small and not sufficiently powered to determine 
whether ST2 concentration would be a good predictor of mortality in AS. However, 3-year 
outcomes for patients in the HF cohort and AS with an LVEF > 50% were similar. ST2 
concentrations were also similar. The 3-year outcome was significantly worse for AS patients 
with impaired LV systolic function, and the baseline ST2 concentrations were significantly 
higher. A repeat of the analysis using a cut-off value of 40% for the LVSD generated similar 
results. The ST2 concentrations appeared to be independent of LV mass, which was an 
echocardiographically derived value, and were independent of diabetes, eGFR, QRS duration, 
EF and age. 
ST2 is thought to be a marker of fibrosis, but not hypertrophy; hence, ST2 may be a 
useful marker for fibrotic disease or the lack of response to aortic valve intervention in AS 
and HF [5]. This should be investigated in a future prospective study as levels of fibrosis 
were not measured in this study. Raised ST2 concentrations, however, did not appear to 
predict group outcomes in the current study. This was surprising and may reflect the  
relatively small sample size in this study. In the future, there may be a role for combining 
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ST2 and NT-proBNP levels to provide clinicians with additional information for the 
management of cardiovascular disease [15]. 
ST2 has emerged as marker of inflammation, fibrosis, cardiac stress and remodeling. 
In many studies ST2 has been shown to be BNP independent predictor of cardiac and all-
cause mortality. ST2 reflects dynamic changes in a failing heart and thus, parallel the 
myocardial remodeling and risk of cardiac events. Its value is potentially more significant in 
HEpEF and patients with LVH.  
Undertaking serial measurements of the ST2 concentrations did not appear to show 
significant differences in concentrations, but analysis of the data revealed that ST2 
concentration changed from –99 to 29 mcg/L in patients who had undergone TAVI, which 
indicates a large variation within a small population. While the results may have been 
influenced by statistical outliers, many patients did not show significant changes in their ST2 
concentrations post-TAVI. 
 
Limitations of the study 
One limitation of the current study was the small sample size of the HF cohort, which 
was a consequence of strict inclusion criteria for the study. Furthermore, this study was an 
observational cohort study and its results are, therefore, subject to undetermined confounding 
factors; and hence, should be interpreted with caution. It is acknowledged that average ages 
of the HF and AS cohorts were very different. However, since TAVI is a life-extending and, 
sometimes, life-saving procedure, it was believed that a 3-year follow-up duration was a 
reasonable life expectancy post-TAVI for patients selected to undergo the procedure. It was 
also recognized that this study did not include a healthy control group. However, these data 
are hypothesis generating and they will support a much larger prospective study that is 
designed to determine the effects of changing ST2 levels on the outcomes in this population. 
 
Conclusions 
The serum ST2 concentrations are elevated to similar levels in patients with severe 
LVSD and in the population of patients with severe AS who underwent TAVI. The 
concentrations were highest in patients with severe LVSD and severe AS. This is the first 
study to compare ST2 concentrations in optimally treated patients with stable but significant 
LV dysfunction with those in patients with severe AS. Raised ST2 concentrations from 
increased biomechanical stress on the myocardium in the context of severe AS may be a 
marker for subclinical or clinical left ventricular dysfunction.  
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Ongoing biomarker research in this area should focus solely on replacing NT-proBNP 
or even troponin, but rather on investigating early pathophysiological changes in the 
myocardium, which may lead to future therapeutic targets. It is tempting to speculate that 
early detection of disease progression using novel biomarkers or significant changes in 
interval testing may be of future clinical relevance, but larger prospective studies will be 
required to address these gaps in knowledge. 
 
Acknowledgements 
This work was funded by King’s College Hospital R&D Grant, and was supported by 
the Department of Health via a National Institute for Health Research Biomedical Research 
Centre award to Guy’s & St Thomas’ NHS Foundation Trust in partnership with King’s 
College London and King’s College Hospital NHS Foundation Trust 
 
Conflict of interest: None declared 
 
 
References 
1. Januzzi JL, Mebazaa A, Di Somma S. ST2 and prognosis in acutely decompensated heart failure: the 
International ST2 Consensus Panel. Am J Cardiol. 2015; 115(7 Suppl): 26B–31B, 
doi: 10.1016/j.amjcard.2015.01.037, indexed in Pubmed: 25665762. 
2. Zhang R, Zhang Y, An T, et al. Prognostic value of sST2 and galectin-3 for death relative to renal 
function in patients hospitalized for heart failure. Biomark Med. 2015; 9(5): 433–441, 
doi: 10.2217/bmm.15.12, indexed in Pubmed: 25985174. 
3. Ky B, French B, McCloskey K, et al. High-sensitivity ST2 for prediction of adverse outcomes in chronic 
heart failure. Circ Heart Fail. 2011; 4(2): 180–187, doi: 10.1161/CIRCHEARTFAILURE.110.958223, 
indexed in Pubmed: 21178018. 
4. Januzzi JL, Pascual-Figal D, Daniels LB. ST2 testing for chronic heart failure therapy monitoring: the 
International ST2 Consensus Panel. Am J Cardiol. 2015; 115(7 Suppl): 70B–75B, 
doi: 10.1016/j.amjcard.2015.01.044, indexed in Pubmed: 25670638. 
5. Piper SE, Sherwood RA, Amin-Youssef GF, et al. Serial soluble ST2 for the monitoring of 
pharmacologically optimised chronic stable heart failure. Int J Cardiol. 2015; 178: 284–291, 
doi: 10.1016/j.ijcard.2014.11.097, indexed in Pubmed: 25465308. 
6. Bartunek J, Delrue L, Van Durme F, et al. Nonmyocardial production of ST2 protein in human 
hypertrophy and failure is related to diastolic load. J Am Coll Cardiol. 2008; 52(25): 2166–2174, 
doi: 10.1016/j.jacc.2008.09.027, indexed in Pubmed: 19095135. 
7. Shimpo M, Morrow DA, Weinberg EO, et al. Expression and regulation of ST2, an interleukin-1 receptor 
family member, in cardiomyocytes and myocardial infarction. Circulation. 2002; 106(23): 2961–2966, 
indexed in Pubmed: 12460879. 
8. McMurray JJV, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of 
acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and 
Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the 
Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012; 14(8): 803–869, 
doi: 10.1093/eurjhf/hfs105, indexed in Pubmed: 22828712. 
9 
 
9. R & D Systems. Human ST2/IL-33 R Quantikine ELISA 
Kit. https://www.rndsystems.com/products/human-st2-il-33-r-quantikine-elisa-kit_dst200(Accessed 
03/11/2018). 
10. Horstkotte D, Loogen F. The natural history of aortic valve stenosis. Eur Heart J. 1988; 9 Suppl E: 57–
64, doi: 10.1093/eurheartj/9.suppl_e.57, indexed in Pubmed: 3042404. 
11. Bayes-Genis A, Januzzi JL, Gaggin HK, et al. ST2 pathogenetic profile in ambulatory heart failure 
patients. J Card Fail. 2015; 21(4): 355–361, doi: 10.1016/j.cardfail.2014.10.014, indexed in 
Pubmed: 25451702. 
12. Sawada H, Naito Y, Hirotani S, et al. Expression of interleukin-33 and ST2 in nonrheumatic aortic valve 
stenosis. Int J Cardiol. 2013; 168(1): 529–531, doi: 10.1016/j.ijcard.2012.12.059, indexed in 
Pubmed: 23332814. 
13. Carabello BA. Is it ever too late to operate on the patient with valvular heart disease? J Am Coll Cardiol. 
2004; 44(2): 376–383, doi: 10.1016/j.jacc.2004.03.061, indexed in Pubmed: 15261934. 
14. Lancellotti P, Dulgheru R, Magne J, et al. Elevated plasma soluble ST2 is associated with heart failure 
symptoms and outcome in aortic stenosis. PLoS One. 2015; 10(9): e0138940, 
doi: 10.1371/journal.pone.0138940, indexed in Pubmed: 26390433. 
15. Ibrahim N, Januzzi JL. The potential role of natriuretic peptides and other biomarkers in heart failure 
diagnosis, prognosis and management. Expert Rev Cardiovasc Ther. 2015; 13(9): 1017–1030, 
doi: 10.1586/14779072.2015.1071664, indexed in Pubmed: 26198476. 
 
 
 
 
Table 1. Baseline characteristics of study population. 
Variable HF (n = 50) 
AS, EF > 
50% (n = 63) 
AS, EF < 
50% (n = 31) 
Total (n = 
144) P 
Age [years]* 68.5 (21) 85.0 (8) 86.0 (7) 81.00 (15) < 0.001 
Male 82.0% 54.0% 45.2% 61.8% 0.001 
Diabetes mellitus 16.0% 22.2% 25.8% 20.8% 0.536 
Hypertension 50.0% 52.4% 51.6% 51.4% 0.968 
Dyslipidemia 56.0% 28.6% 16.1% 35.4% < 0.001 
NYHA class: 
        I 10.0% 1.6% 0.0% 4.2% < 0.001 
        II 70.0% 25.4% 12.9% 38.2%  
       III 20.0% 71.4% 74.2% 54.2%  
       IV 0.0% 1.6% 12.9% 3.5%  
Systolic BP [mmHg]** 
116.88 
(19.4) 132.89 (22.1) 125.90 (25.2) 
125.83 
(22.9) 0.001 
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Diastolic BP [mmHg]** 68.12 (10.7) 68.73 (11.9) 68.61 (14.5) 
68.49 
(12.0) 0.963 
Heart rate [bpm]* 66.00 (18) 74.00 (17) 71.00 (16) 70.00 (20) 0.026 
ICD (not CRT-D) 14.0 0.0 0.0 4.9 0.001 
PPM 8.0 14.3 12.9 11.8 0.576 
CRT 28.0 0.0 6.5 11.1 < 0.001 
Sinus rhythm 76.0 65.1 54.8 66.7 0.039 
Baseline QRS [ms]* 118.50 (68)  96.00 (35) 119.00 (52) 
110.00 
(49) < 0.001 
eGFR [mL/min/1.73 
m2]* 62.0 (26) 64.0 (26) 51.0 (33) 61.50 (28) 0.253 
Hemoglobin [g/L]** 137.2 ± 14.2  122.38 ± 16.0 124.32 ± 16.2 
127.94 ± 
16.8 < 0.001 
LV mass [g]* 248.5 (93.0) 253.3 (76.9) 280.6 (103.0) 
198.76 
(147) 0.03 
Baseline EF [%]* 31.50 (11) 59.00 (8) 42.00 (12) 45.00 (23) < 0.001 
Baseline NT-pro-BNP 
[ng/L]* 
300.00 
(1201) 
1756.00 
(3353) 
5263.00 
(11907) 
1446.00 
(3862) < 0.001 
Na+ [mmol/L]* 138.50 (5) 138.0 (4) 137.00 (5) 138.00 (4) 0.099 
The data presented are the medians and the interquartile ranges (*) or the means and standard deviations (**). 
AS — aortic stenosis; BP — blood pressure; CRT — cardiac resynchronization therapy; CRT-D — cardiac 
resynchronization therapy-defibrillator; eGFR — estimated glomerular filtration rate; EF — ejection fraction; 
ICD — implantable cardiac defibrillator; LV — left ventricular; Na — sodium; NT-proBNP — N-terminal pro-
B-type natriuretic peptide; NYHA — New York Heart Association; PPM — permanent pacemaker 
 
 
 
Table 2. Stepwise multivariate linear regression analysis of the baseline sST2 concentration. 
  Non-standardized 
coefficient 
Standardize
d coefficient 
T-
statistic 
P value 
  Beta SE[A1]  Beta   
NYHA IV 34.6 8.3 0.41 4.12 < 0.001 
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Male gender 11.7 3.7 0.31 3.13 0.003 
NT-pro-BNP [ng/L] 0.001 0.0 0.40 4.01 < 0.001 
NT-proBNP — N-terminal pro–B-type natriuretic peptide; NYHA — New York Heart Association; SE — 
standard error 
 
 
Figure 1. Box plots of the cohort median ST2 concentrations using a left ventricular ejection 
fraction (LVEF) cut-off value of < 50%. The Kruskal-Wallis test indicated that the difference 
between the patients with heart failure (HF) and those with aortic stenosis (AS) and a low 
ejection fraction with respect to ST2 concentration was significant (p = 0.009).  
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Figure 2. Box plots of the cohort baseline ST2 concentrations using a left ventricular systolic 
dysfunction (LVSD) cut-off value of < 40%. The Kruskal-Wallis test indicated that the 
difference between the patients with heart failure (HF) and those with aortic stenosis (AS) 
and LVSD with respect to the ST2 concentration was significant (p = 0.049); LVEF — left 
ventricular ejection fraction. 
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Figure 3. Kaplan-Meier plots for the cohorts split at the median ST2 concentration. The 
green line is the high ST2 concentration, and the blue line is the low ST2 concentration.
 
 
 
 
Figure 4. Kaplan-Meier plots of survival probability of the cohorts using a left ventricular 
systolic dysfunction (LVSD) cut-off value of left ventricular ejection fraction (LVEF) < 50%. 
The blue line represents the heart failure group, the green line represents the aortic stenosis 
(AS) group without LVSD, and the yellow line represents the AS group with LVSD. The 
scale of the x-axis is in days up to 3 years. 
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Figure 5. Kaplan-Meier plots of the survival probability of the patient population according 
to baseline N-terminal pro-B-type natriuretic peptide (NT-proBNP). This was split at the NT-
proBNP median concentration, up to the time at which the data were censored, which was 3 
years. The blue line represents patients with NT-proBNP concentration above median and the 
green line represent the patients with NT-proBNP concentration below median. 
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